Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21st March 2012 The ATLAS ACS 2-TIMI 51 trial (n = 15,526) found that rivaroxaban at twice daily doses of 2.5 mg or 5 mg, in addition to standard […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 February 2012 A randomised, double-blind, 30-week, phase III trial (n = 261) found that adding twice-daily exenatide to basal insulin therapy with insulin glargine improved HbA1c levels in […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21 December 2011 Summary: Data from the two year TEMSO trial have shown that teriflunomide, a once daily oral drug for the treatment of relapsing forms of multiple sclerosis, […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 November 2011 The ARISTOTLE study found that apixaban▼ 5 mg twice a day reduced the risk of the composite outcome of ischaemic or haemorrhagic stroke or systemic embolism […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 October 2011 The published data from ROCKET AF in 14,264 patients with nonvalvular atrial fibrillation (AF), who were at moderate to high risk of stroke, found that rivaroxaban […]